Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.

Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, Coussens LM, Brockstedt DG.

Clin Cancer Res. 2019 Oct 1;25(19):5787-5798. doi: 10.1158/1078-0432.CCR-19-0070. Epub 2019 Jul 1.

PMID:
31263030
2.

A Potent and Effective Suicidal Listeria Vaccine Platform.

Hanson WG, Benanti EL, Lemmens EE, Liu W, Skoble J, Leong ML, Rae CS, Fassò M, Brockstedt DG, Chen C, Portnoy DA, Dubensky TW Jr, Lauer P.

Infect Immun. 2019 Jul 23;87(8). pii: e00144-19. doi: 10.1128/IAI.00144-19. Print 2019 Aug.

3.

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).

Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ 3rd, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM.

Clin Cancer Res. 2019 Sep 15;25(18):5493-5502. doi: 10.1158/1078-0432.CCR-18-2992. Epub 2019 May 24.

PMID:
31126960
4.

Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.

Kim VM, Blair AB, Lauer P, Foley K, Che X, Soares K, Xia T, Muth ST, Kleponis J, Armstrong TD, Wolfgang CL, Jaffee EM, Brockstedt D, Zheng L.

J Immunother Cancer. 2019 May 22;7(1):132. doi: 10.1186/s40425-019-0601-5.

5.

Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming.

Johnson LE, Brockstedt D, Leong M, Lauer P, Theisen E, Sauer JD, McNeel DG.

Oncoimmunology. 2018 May 7;7(8):e1456603. doi: 10.1080/2162402X.2018.1456603. eCollection 2018.

6.

Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.

Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, Schell TD, Garbi N, Greenberg PD.

Immunity. 2016 Aug 16;45(2):389-401. doi: 10.1016/j.immuni.2016.07.011. Epub 2016 Aug 9.

7.

Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination.

Jackson CM, Kochel CM, Nirschl CJ, Durham NM, Ruzevick J, Alme A, Francica BJ, Elias J, Daniels A, Dubensky TW Jr, Lauer P, Brockstedt DG, Baxi EG, Calabresi PA, Taube JM, Pardo CA, Brem H, Pardoll DM, Lim M, Drake CG.

Clin Cancer Res. 2016 Mar 1;22(5):1161-72. doi: 10.1158/1078-0432.CCR-15-1516. Epub 2015 Oct 21.

8.

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM.

J Clin Oncol. 2015 Apr 20;33(12):1325-33. doi: 10.1200/JCO.2014.57.4244. Epub 2015 Jan 12.

9.

Attenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus.

Miller EA, Spadaccia MR, Norton T, Demmler M, Gopal R, O'Brien M, Landau N, Dubensky TW Jr, Lauer P, Brockstedt DG, Bhardwaj N.

AIDS Res Hum Retroviruses. 2015 Jan;31(1):127-36. doi: 10.1089/AID.2014.0138.

10.
11.

Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis.

Lizotte PH, Baird JR, Stevens CA, Lauer P, Green WR, Brockstedt DG, Fiering SN.

Oncoimmunology. 2014 May 23;3:e28926. eCollection 2014.

12.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong TD, Jaffee EM.

Gastroenterology. 2014 Jun;146(7):1784-94.e6. doi: 10.1053/j.gastro.2014.02.055. Epub 2014 Mar 6.

13.

Enhanced virus-specific CD8+ T cell responses by Listeria monocytogenes-infected dendritic cells in the context of Tim-3 blockade.

Ma CJ, Ren JP, Li GY, Wu XY, Brockstedt DG, Lauer P, Moorman JP, Yao ZQ.

PLoS One. 2014 Jan 31;9(1):e87821. doi: 10.1371/journal.pone.0087821. eCollection 2014.

14.

Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation.

Cohn L, Chatterjee B, Esselborn F, Smed-Sörensen A, Nakamura N, Chalouni C, Lee BC, Vandlen R, Keler T, Lauer P, Brockstedt D, Mellman I, Delamarre L.

J Exp Med. 2013 May 6;210(5):1049-63. doi: 10.1084/jem.20121251. Epub 2013 Apr 8.

15.

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies.

Bot A, Ahn M, Bosch M, Brockstedt D, Butterfield LH, Cornforth A, Harrop R, Kast WM, Koya R, Marincola F, Margolin K, McCoy C, Pawelec G, Rothman J, Ramirez-Montagut T, Schlom J, Srivastava P, Wallis S, Walter S, Wang E, Waslif J.

J Transl Med. 2012 Nov 5;10:218. doi: 10.1186/1479-5876-10-218.

16.

Killed but metabolically active vaccines.

Dubensky TW Jr, Skoble J, Lauer P, Brockstedt DG.

Curr Opin Biotechnol. 2012 Dec;23(6):917-23. doi: 10.1016/j.copbio.2012.04.005. Epub 2012 May 18. Review.

PMID:
22608846
17.

Clinical development of Listeria monocytogenes-based immunotherapies.

Le DT, Dubenksy TW Jr, Brockstedt DG.

Semin Oncol. 2012 Jun;39(3):311-22. doi: 10.1053/j.seminoncol.2012.02.008. Review.

18.

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.

Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW Jr, Eiden JE, Jaffee EM, Laheru DA.

Clin Cancer Res. 2012 Feb 1;18(3):858-68. doi: 10.1158/1078-0432.CCR-11-2121. Epub 2011 Dec 6.

19.

Tumor-associated antigen expressing Listeria monocytogenes induces effective primary and memory T-cell responses against hepatic colorectal cancer metastases.

Olino K, Wada S, Edil BH, Pan X, Meckel K, Weber W, Slansky J, Tamada K, Lauer P, Brockstedt D, Pardoll D, Schulick R, Yoshimura K.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S597-607. doi: 10.1245/s10434-011-2037-0. Epub 2011 Oct 7.

20.

Interplay between CD8α+ dendritic cells and monocytes in response to Listeria monocytogenes infection attenuates T cell responses.

Kapadia D, Sadikovic A, Vanloubbeeck Y, Brockstedt D, Fong L.

PLoS One. 2011 Apr 29;6(4):e19376. doi: 10.1371/journal.pone.0019376.

21.

Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.

Sinnathamby G, Lauer P, Zerfass J, Hanson B, Karabudak A, Krakover J, Secord AA, Clay TM, Morse MA, Dubensky TW Jr, Brockstedt DG, Philip R, Giedlin M.

J Immunother. 2009 Oct;32(8):856-69. doi: 10.1097/CJI.0b013e3181b0b125.

PMID:
19752748
22.

Suppression of cell-mediated immunity following recognition of phagosome-confined bacteria.

Bahjat KS, Meyer-Morse N, Lemmens EE, Shugart JA, Dubensky TW, Brockstedt DG, Portnoy DA.

PLoS Pathog. 2009 Sep;5(9):e1000568. doi: 10.1371/journal.ppat.1000568. Epub 2009 Sep 4.

23.

Impact of preexisting vector-specific immunity on vaccine potency: characterization of listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice.

Leong ML, Hampl J, Liu W, Mathur S, Bahjat KS, Luckett W, Dubensky TW Jr, Brockstedt DG.

Infect Immun. 2009 Sep;77(9):3958-68. doi: 10.1128/IAI.01274-08. Epub 2009 Jun 15.

24.

KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.

Skoberne M, Yewdall A, Bahjat KS, Godefroy E, Lauer P, Lemmens E, Liu W, Luckett W, Leong M, Dubensky TW, Brockstedt DG, Bhardwaj N.

J Clin Invest. 2008 Dec;118(12):3990-4001. doi: 10.1172/JCI31350. Epub 2008 Nov 6.

25.

Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.

Brockstedt DG, Dubensky TW.

Expert Rev Vaccines. 2008 Sep;7(7):1069-84. doi: 10.1586/14760584.7.7.1069. Review.

PMID:
18767955
26.

Constitutive Activation of the PrfA regulon enhances the potency of vaccines based on live-attenuated and killed but metabolically active Listeria monocytogenes strains.

Lauer P, Hanson B, Lemmens EE, Liu W, Luckett WS, Leong ML, Allen HE, Skoble J, Bahjat KS, Freitag NE, Brockstedt DG, Dubensky TW Jr.

Infect Immun. 2008 Aug;76(8):3742-53. doi: 10.1128/IAI.00390-08. Epub 2008 Jun 9.

27.

Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease.

Bahjat KS, Prell RA, Allen HE, Liu W, Lemmens EE, Leong ML, Portnoy DA, Dubensky TW Jr, Brockstedt DG, Giedlin MA.

J Immunol. 2007 Dec 1;179(11):7376-84.

28.

Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.

Goldberg MV, Maris CH, Hipkiss EL, Flies AS, Zhen L, Tuder RM, Grosso JF, Harris TJ, Getnet D, Whartenby KA, Brockstedt DG, Dubensky TW Jr, Chen L, Pardoll DM, Drake CG.

Blood. 2007 Jul 1;110(1):186-92. Epub 2007 Mar 28.

29.

Cytosolic entry controls CD8+-T-cell potency during bacterial infection.

Bahjat KS, Liu W, Lemmens EE, Schoenberger SP, Portnoy DA, Dubensky TW Jr, Brockstedt DG.

Infect Immun. 2006 Nov;74(11):6387-97. Epub 2006 Sep 5.

30.

Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity.

Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M, Brockstedt D, Dubensky TW, Stins MF, Lanier LL, Pardoll DM, Housseau F.

Nat Med. 2006 Feb;12(2):207-13. Epub 2006 Jan 29.

PMID:
16444266
31.

Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes.

Yoshimura K, Jain A, Allen HE, Laird LS, Chia CY, Ravi S, Brockstedt DG, Giedlin MA, Bahjat KS, Leong ML, Slansky JE, Cook DN, Dubensky TW, Pardoll DM, Schulick RD.

Cancer Res. 2006 Jan 15;66(2):1096-104.

32.

Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity.

Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G, Lim JY, Sampson-Johannes A, Herskovits AA, Stassinopoulos A, Bouwer HG, Hearst JE, Portnoy DA, Cook DN, Dubensky TW Jr.

Nat Med. 2005 Aug;11(8):853-60. Epub 2005 Jul 24.

PMID:
16041382
33.

Listeria-based cancer vaccines that segregate immunogenicity from toxicity.

Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr.

Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7. Epub 2004 Sep 13.

34.

Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes.

Auerbuch V, Brockstedt DG, Meyer-Morse N, O'Riordan M, Portnoy DA.

J Exp Med. 2004 Aug 16;200(4):527-33. Epub 2004 Aug 9.

35.

Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy.

Starks H, Bruhn KW, Shen H, Barry RA, Dubensky TW, Brockstedt D, Hinrichs DJ, Higgins DE, Miller JF, Giedlin M, Bouwer HG.

J Immunol. 2004 Jul 1;173(1):420-7.

36.

Development of anti-tumor immunity against a non-immunogenic mammary carcinoma through in vivo somatic GM-CSF, IL-2, and HSVtk combination gene therapy.

Brockstedt DG, Diagana M, Zhang Y, Tran K, Belmar N, Meier M, Yang A, Boissiere F, Lin A, Chiang Y.

Mol Ther. 2002 Nov;6(5):627-36.

37.

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy.

Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG.

J Immunol. 2001 Dec 15;167(12):7150-6.

38.

Dendritic cells injected via different routes induce immunity in cancer patients.

Fong L, Brockstedt D, Benike C, Wu L, Engleman EG.

J Immunol. 2001 Mar 15;166(6):4254-9.

39.

Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration.

Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman EG.

Clin Immunol. 1999 Jul;92(1):67-75.

PMID:
10413654
40.

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.

Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM.

Nat Med. 1999 Jun;5(6):677-85.

PMID:
10371507
41.
42.

Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide.

Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB.

J Immunol. 1997 Aug 15;159(4):1666-8.

PMID:
9257826

Supplemental Content

Loading ...
Support Center